Pharmacogenomics and drug safety
New drugs go through clinical trials before they can be marketed. Phase I trials are for safety. Phase II/III trials are for efficacy. If a drug fails these trials, it can’t be sold. One challenge to drug testing is trial enrollment. Ideally, the subjects should be demographically representative. The problem is that there can be […]